ATNX To Face FDA In Feb, ICPT Trims Workforce, JNCE Jumps On GILD Deal, SNY's Kevzara Flops Again

Today's Daily Dose brings you news about regulatory catalysts of Athenex and Vertex Pharma, layoffs in Intercept, licensing deal between Jounce and Gilead, and Sanofi's repurposed arthritis drug failing to meet goals in the COVID-19 trial.

from RTT - Biotech https://ift.tt/3gQMpqe
via IFTTT